Cardiovascular Risk After Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Investigation of cardiovascular risk 5-15 years after early or late-onset preeclampsia by adenosine stress Magnetic Resonance Imaging and non-invasive methods like retinal vessel analysis, skin measurement of advanced glycation end products, flow-mediated dilation or pulse wave analysis in comparison to women after healthy pregnancies.

Official Title
-----------------
Endothelial Dysfunction and Cardiovascular Risk After Preeclampsia

Conditions
-----------------
Preeclampsia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women 18-60 years 5-15 years postpartum Exclusion Criteria: Atrioventricular block, chronic obstructive pulmonary disease, bronchial asthma Pregnancy and/or active breastfeeding Glaucoma disease, epilepsy In addition for MRI: metal implants, electric devices, intolerance of contrast media, claustrophobia, renal or hepatic dysfunction (GFR < 30 ml/min)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early-onset preeclampsia<br>Defined as preeclampsia that develops before 34 weeks of gestation | |
| Late-onset preeclampsia<br>Defined as preeclampsia that develops after 34 weeks of gestation | |
| Control<br>Healthy pregnancies, matched to early and late-onset cases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myocardial perfusion | Measured by adenosine stress Magnetic Resonance Imaging (ml/min/g) | Day 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac fibrosis | Measured by Magnetic Resonance Imaging (g) | Day 2 | 
| Immune cell phenotypes | Measured in isolated peripheral blood mononuclear cells | Day 1 | 
| Concentration of N-terminal prohormone of brain natriuretic peptide | Measured in serum (ng/l) | Day 1 | 
| Concentration of brain natriuretic peptide | Measured in serum (ng/l) | Day 1 | 
| Urinary protein | Measured in spot urine (mg) | Day 1 | 
| Advanced glycation end products | Measured by skin autofluorescence (arbitrary units) | Day 1 | 
| Body fat mass | Measured by bioimpedance analysis (%) | Day 1 | 
| Body fat-free mass | Measured by bioimpedance analysis (%) | Day 1 | 
| Hand grip strength | Measured by dynamometer (kg) | Day 1 | 
| Systolic blood pressure | Mean of three consecutive blood pressure measurements (mmHg) | Day 1 | 
| Diastolic blood pressure | Mean of three consecutive blood pressure measurements (mmHg) | Day 1 | 
| Pulse wave velocity | Calculated by algorithm based on age and blood pressure values (m/s) | Day 1 | 
| Flow-mediated dilation | Measured by brachial artery diameter (µm) | Day 1 | 
| Reactive hyperemia index | Measured by finger plethysmography | Day 1 | 
| Choroidal thickness | Measured with Optical Coherence Tomography (µm) | Day 1 | 
| Macular volume | Measured with Optical Coherence Tomography (mm³) | Day 1 | 
| Arterial dilation induced by retinal flicker stimulation | Measured with Dynamic Vessel Analyser (seconds) | Day 1 | 
| Venous dilation induced by retinal flicker stimulation | Measured with Dynamic Vessel Analyser (seconds) | Day 1 |